PM Bhartiya Janaushadhi Pariyojana

Indian Economy glossary

Also called: Jan Aushadhi, PMBJP · Topic: Human Capital: Education, Health and Demographic Dividend · NCERT: Beyond NCERT

Meaning

PM Bhartiya Janaushadhi Pariyojana (PMBJP) is a central government scheme that sells good-quality generic medicines at low prices through dedicated shops called Jan Aushadhi Kendras. A generic medicine has the same active ingredient, strength and effect as a branded drug, but it is sold under its salt (chemical) name. The Department of Pharmaceuticals, under the Ministry of Chemicals & Fertilizers, runs the scheme.

It matters because medicines are a large part of what Indian families pay for health from their own pockets. When drugs are cheaper, families are less likely to fall into poverty or skip treatment, and that protects human capital (the health and skills that make workers productive).

Explanation

What problem it solves

Out-of-pocket expenditure (OOPE) is money a family pays directly at the time of treatment, with no insurance or government cover.
The chain: illness → family buys costly branded medicines → savings run out or the family borrows → treatment is cut short → the worker loses health and income.
Health spending directly adds to the supply of healthy labour. A sick worker without care stays away from work, and output is lost (Class 11).
High OOPE pushes families into poverty and makes them skip care, which erodes human capital.

How the scheme works

Product: generic medicines, plus some surgical and medical items, sold under the "Jan Aushadhi" label.
Procurement: an implementing agency under the Department of Pharmaceuticals, the Pharmaceuticals & Medical Devices Bureau of India (PMBI), buys the medicines in bulk straight from manufacturers.
Buying in bulk lowers the purchase price.
Medicines move through the scheme's own supply chain, so fewer middlemen take a margin.
Quality check: batches are tested in accredited laboratories before sale. This answers the common fear that "cheap means poor quality".
Outlets: Jan Aushadhi Kendras are opened by individual pharmacists, entrepreneurs, NGOs, hospitals and similar bodies. They sell only at the scheme's fixed low prices.

Why generics are cheaper

A branded drug's price includes marketing, brand promotion and large trade margins (the gap between the price at which the manufacturer sells and the MRP the patient pays).
A generic sold under its salt name carries no brand premium, so the patient pays mainly for the medicine itself.
What makes the scheme work better or worse:
Works better when: doctors write salt names on prescriptions, Kendras keep stock, and people trust the quality.
Works worse when: Kendras run out of stock, doctors prescribe brands, or patients believe generics are weaker.

In India

Ministry in charge: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers. This is the same department under which the National Pharmaceutical Pricing Authority (NPPA) works. It is not the Ministry of Health & Family Welfare.
Why it is needed:
Under National Health Accounts 2021-22, out-of-pocket spending was about 39% of total health spending, down from about 64% in 2013-14 (verify current).
Government health spending is about 1.8% of GDP, against the NHP 2017 target of 2.5% of GDP by 2025.
Cancer care shows the gap clearly:
About 65% of spending on cancer care is out-of-pocket.
About 60% of households borrow money for cancer hospital stays.
Its place in drug affordability policy: India has three separate tools.
Price regulation: NPPA, through DPCO 2013. It capped trade margins at 30% for 42 cancer drugs in 2019 and for 137 non-scheduled anti-cancer drugs in 2026.
Insurance: Ayushman Bharat PM-JAY (2018), hospital cover of ₹5 lakh per family per year.
Direct supply of cheap generics: Jan Aushadhi outlets. Cancer care is delivered through PM-JAY package rates, state drug controllers and Jan Aushadhi outlets together.

Don't confuse with

NPPA / DPCO price control: NPPA orders a ceiling price or margin cap that every seller of the drug must follow. Jan Aushadhi sells its own generics at low prices through its own shops. One is a rule; the other is supply.
Ayushman Bharat PM-JAY: PM-JAY is insurance that pays for hospital stays and procedures. Jan Aushadhi lowers the cost of medicines bought at a shop. Neither one covers what the other does.
Branded generics: these are off-patent drugs that private companies sell under their own brand names, often at much higher prices. Jan Aushadhi medicines are sold under their salt names, without a brand premium.
PM-JAY's Ayushman Arogya Mandirs: these are primary-care centres (renamed Health and Wellness Centres) that provide care. Jan Aushadhi Kendras are pharmacies that only sell medicines.

Prelims Hooks

PMBJP is run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, not the Ministry of Health & Family Welfare. This is a common trap.
Its implementing agency is the Pharmaceuticals & Medical Devices Bureau of India (PMBI), which buys the medicines and runs the supply chain.
The outlets are called Jan Aushadhi Kendras. They sell generic medicines, meaning the same salt, strength and effect as branded drugs, under the salt name.
Trap: "Jan Aushadhi fixes ceiling prices for all medicines sold in India" is FALSE. Ceiling prices and trade-margin caps are fixed by NPPA under DPCO 2013.
Trap: "Jan Aushadhi provides hospital insurance" is FALSE. Hospital cover of ₹5 lakh per family per year comes under PM-JAY (2018).
NHA 2021-22: OOPE is about 39% of total health spending, down from about 64% (2013-14). Cutting medicine costs is one way to reduce it.

Mains Points

Three tools for affordable medicines: price regulation (NPPA's margin caps), insurance (PM-JAY) and direct supply of cheap generics (Jan Aushadhi) work together. None is enough alone.
Margin caps leave the manufacturer's own price untouched.
PM-JAY covers hospital stays but not everyday outpatient medicines.
Jan Aushadhi lowers drug bills only where a Kendra exists and has stock.
Getting from a cheap shelf to an actual cheaper bill: the scheme's impact depends on three things.
Doctors must prescribe salt names.
Kendras need reliable stock, especially in rural areas.
Patients must trust that generics are as good as brands. Visible quality testing and public awareness campaigns (social medicine, meaning the spreading of health literacy) build that trust.
Link to human capital and the demographic dividend: lower OOPE means fewer families fall into poverty or skip care, and workers stay healthy for longer. This supports the goal of turning India's young population (65% below 35, ES 2024) into productive human capital. It also backs NHP 2017's aim of reducing families' financial burden, given that public health spending is only about 1.8% of GDP.

Human Capital: Education, Health and Demographic Dividend